Screener
Artiva Biotherapeutics, Inc. ARTV Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The source filing: Artiva Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338029
| PERIOD ENDED JUNE 30, | |
|---|---|
| 2027 | 3,497 |
| 2028 | 3,603 |
| 2029 | 2,284 |
| Total minimum lease payments | 11,090 |
| Less: amount representing interest | (1,241) |
| Present value of operating lease liabilities | 9,849 |
| Less: operating lease liabilities, current | (3,299) |
| Operating lease liabilities, net of current portion | $6,550 |
Item 1. Financial Statements
FAQ
- What is Artiva Biotherapeutics, Inc.'s operating lease liability - undiscounted excess amount?
- Artiva Biotherapeutics, Inc. (ARTV) reported operating lease liability - undiscounted excess amount of $1.24M in Q2 2026.
- How has Artiva Biotherapeutics, Inc.'s operating lease liability - undiscounted excess amount changed year-over-year?
- Artiva Biotherapeutics, Inc.'s operating lease liability - undiscounted excess amount decreased by 47.9% year-over-year, from $2.38M to $1.24M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.
Ask your AI about Artiva Biotherapeutics, Inc.'s operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude